mk-1064
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2009 (NCT02549014)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Orexin receptor 2ANTAGONIST
HCRTR2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(CNC(=O)c2cc(-c3cncc(Cl)c3)cnc2-c2ccccn2)nc1OC- Mol. weight
- 461.91 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3338866 ↗
Also known as
- mk-1064
- mk-1064
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02549027 | Phase 1 | Nov 1, 2009 | Merck |
| NCT02549014 | Phase 1 | Jul 1, 2009 | Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 2 | 2 | 1 | 2009 |
1 organizations
Page 1 / 1